Study publication | Tumor type | No. of patients analyzed | Odds ratio (95%) for disease progression |
---|---|---|---|
Osterborg et al. 1996[34] | Hematologic | 144 | 1.20 (0.60-2.40) |
Littlewood et al. 2001[35] | Solid (non-hematologic) | 375 | 0.64 (0.40-1.02) |
Pronzato et al. 2010[36] | Breast | 223 | 1.02 (0.46-2.26) |
Vansteenkiste et al. 2002[37] | SCLC and NSCLC | 314 | 0.58 (0.30-1.11) |
Hedenus et al. 2003[38] | Hematologic | 344 | 1.08 (0.66-1.76) |
Vadhan-Raj et al. 2003[39] | Gastric and rectal | 60 | 1.01 (0.35-2.94) |
Chang et al. 2005[40] | Breast | 354 | 0.82 (0.39-1.72) |
Grote et al. 2005[41] | SCLC | 224 | 0.85 (0.50-1.44) |
Leyland-Jones et al. 2005[42] | Breast | 939 | 0.84 (0.64-1.08) |
Osterborg et al. 2005[43] | Hematologic | 343 | 0.74 (0.44-1.25) |
Witzig et al. 2005[44] | Mixed | 344 | 1.20 (0.75-1.91) |
Wilkinson et al. 2006[11] | Ovarian | 181 | 7.47 (0.95-58.54) |
Engert et al. 2007[45] | Hodgkin’s lymphoma | 1303 | 0.86 (0.33-2.24) |
Aapro et al. 2008[46] | Breast | 463 | 1.07 (0.82-1.40) |
Pirker et al. 2008[47] | SCLC | 596 | 0.87 (0.52-1.46) |
Strauss et al. 2008[48] | Cervical | 74 | 0.87 (0.32-2.33) |
Thomas et al. 2008[49] | Cervical | 109 | 1.02 (0.48-2.15) |